JPWO2022019259A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022019259A5
JPWO2022019259A5 JP2022537997A JP2022537997A JPWO2022019259A5 JP WO2022019259 A5 JPWO2022019259 A5 JP WO2022019259A5 JP 2022537997 A JP2022537997 A JP 2022537997A JP 2022537997 A JP2022537997 A JP 2022537997A JP WO2022019259 A5 JPWO2022019259 A5 JP WO2022019259A5
Authority
JP
Japan
Prior art keywords
cancer
her2
antibody
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022537997A
Other languages
English (en)
Japanese (ja)
Other versions
JP7848119B2 (ja
JPWO2022019259A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/026932 external-priority patent/WO2022019259A1/ja
Publication of JPWO2022019259A1 publication Critical patent/JPWO2022019259A1/ja
Publication of JPWO2022019259A5 publication Critical patent/JPWO2022019259A5/ja
Application granted granted Critical
Publication of JP7848119B2 publication Critical patent/JP7848119B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022537997A 2020-07-20 2021-07-19 抗her2抗体-薬物コンジュゲートとher二量体化阻害剤の組み合わせ Active JP7848119B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020123564 2020-07-20
JP2020123564 2020-07-20
PCT/JP2021/026932 WO2022019259A1 (ja) 2020-07-20 2021-07-19 抗her2抗体-薬物コンジュゲートとher二量体化阻害剤の組み合わせ

Publications (3)

Publication Number Publication Date
JPWO2022019259A1 JPWO2022019259A1 (https=) 2022-01-27
JPWO2022019259A5 true JPWO2022019259A5 (https=) 2024-07-30
JP7848119B2 JP7848119B2 (ja) 2026-04-20

Family

ID=79728699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537997A Active JP7848119B2 (ja) 2020-07-20 2021-07-19 抗her2抗体-薬物コンジュゲートとher二量体化阻害剤の組み合わせ

Country Status (11)

Country Link
US (1) US20230293714A1 (https=)
EP (1) EP4183420A4 (https=)
JP (1) JP7848119B2 (https=)
KR (1) KR20230042055A (https=)
CN (1) CN115884794A (https=)
AU (1) AU2021312537A1 (https=)
BR (1) BR112023000982A2 (https=)
CA (1) CA3186675A1 (https=)
IL (1) IL300030A (https=)
TW (1) TW202216214A (https=)
WO (1) WO2022019259A1 (https=)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
IL310627B2 (en) * 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
KR20190066026A (ko) 2016-10-07 2019-06-12 다이이찌 산쿄 가부시키가이샤 항 her2 항체-약물 콘주게이트 투여에 의한 내성암의 치료
US11273155B2 (en) * 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
IL278988B2 (en) 2018-05-28 2024-10-01 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugates for use in the treatment of her-2 mutated cancer
SG11202100653YA (en) 2018-07-25 2021-02-25 Daiichi Sankyo Co Ltd Effective method for manufacturing antibody-drug conjugate

Similar Documents

Publication Publication Date Title
JP2025041725A5 (https=)
JPWO2020122034A5 (https=)
JP2023539715A5 (https=)
IL302078A (en) Anti-CCR8 monoclonal antibodies and their uses
JP2023542066A5 (https=)
JP2023070678A5 (https=)
JP2010535713A5 (https=)
JP2023545096A5 (https=)
JP2017186337A5 (https=)
JP2020502271A5 (https=)
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
HRP20180262T1 (hr) Monoklonska anti-gt468 protutijela za liječenje karcinoma
JP2008531576A5 (https=)
JP2020514310A5 (https=)
JP2014522850A5 (https=)
RU2011111746A (ru) Композиции рекомбинантных антител против рецептора эпидермального фактора роста
HRP20240626T1 (hr) Bispecifična antitijela protiv ceacam5 i cd3
HRP20150256T1 (hr) Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe
JP2014502955A5 (https=)
JP2025092589A5 (https=)
RU2018124319A (ru) Новые антитела к клаудину и способы их применения
RU2020115713A (ru) Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения
JPWO2021177438A5 (https=)
JP2025507817A5 (https=)
JP2024536881A5 (https=)